- Cool Tool – PRIME-XV® T Cell CDM – The First Commercially Available Chemically-defined, Animal-component-free Medium for T Cell CulturePosted 3 hours ago
- Increasing Protein Production with Novel Cell-Ess Titer Boost without Affecting the Metabolic ProfilePosted 5 days ago
- Continuous Processing Optimization with Smarter ToolsPosted 6 days ago
- Cool Tool – Generation of Neural Stem Cells from AlphaSTEM Cultured Pluripotent Stem CellsPosted 1 week ago
- Synergizing Transient and Stable Protein Expression for Accelerated Biotherapeutic DevelopmentPosted 1 week ago
- Cell Culture Dish Top Ten Ask the Expert Sessions and Podcasts of 2016Posted 2 weeks ago
- A Look at the Current State of Continuous BioprocessingPosted 2 weeks ago
- Cool Tool – Biomek i-Series – Next Generation Automated Workstations Specifically Designed to Meet Evolving WorkflowsPosted 2 weeks ago
- Filling Industry Gaps with Dedicated Cell Therapy Fluid Transfer SetsPosted 3 weeks ago
- Cell Culture Monitoring – A Critical Component for Quality by Design in Cell TherapyPosted 3 weeks ago
Recombinant LONG R3IGF‐1 and rTransferrin Improved Growth and Productivity of Two Suspension Chinese Hamster Ovary Cell lines
Jinghui Qian, Rina Gandhi, Ariane Marolewski
LONG®R3IGF‐1 is a human IGF‐1 analog containing a 13 amino acid N‐terminal extension and a mutation at position 3. It activates the Type 1 IGF receptor, which is responsible for growth‐promoting and protein synthesis effects in CHO cells. A common growth factor supplement used in CHO media, insulin, acts primarily through the IGF‐R.
LONG®R3IGF‐1 has previously been shown to increase CHO productivity. However, past characterization studies used primarily DMEM/F12 media. As serum‐free media development has progressed, media have become richer and more complex. To establish the effect of LONG®R3IGF‐1 in media that meet today’s industry standards, the effect of LONG®R3IGF‐1 on the productivity of two antibody‐expressing cell lines was compared to that of insulin and no growth factor supplemented media. The studies were carried out in TPP Tubespin50mL bioreactor tubes. Media with LONG®R3IGF‐1 gave superior titers versus no growth factor or insulin in several instances. In addition, it was demonstrated that combination of LONG®R3IGF‐1 and rTransferrin gave higher titer than commercial ITS (rInsulin, rTransferrin, Selenium) solution in several modern commercial media types.
LONG®R3IGF‐1 is used at low, 10 –100 ng/mL, concentrations in cell culture and is currently used in several commercial antibody manufacturing processes. It represents a regulatory‐friendly method of enhancing serum‐free cell culture performance. LONG®R3IGF‐1 should, therefore, be considered as a media supplement to further optimize a protein‐free process or to replace insulin in existing processes.